Ethic Inc. Invests $482,000 in Doximity, Inc. $DOCS

Key Points

• Ethic Inc. acquired 8,492 shares of Doximity, Inc. worth approximately $482,000 during the first quarter.
• Insider transactions reveal that Director Regina M. Benjamin sold 5,000 shares at an average price of $63.00, reducing her stake by 23.13%.
• Wall Street analysts have given Doximity a consensus rating of "Moderate Buy" with a price target of $66.21, reflecting mixed sentiment across different firms.

Ethic Inc. purchased a new stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 8,492 shares of the company's stock, valued at approximately $482,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Doximity by 8.8% in the 1st quarter. Vanguard Group Inc. now owns 12,194,492 shares of the company's stock valued at $707,646,000 after buying an additional 990,923 shares during the last quarter. Invesco Ltd. increased its stake in shares of Doximity by 54.8% during the 1st quarter. Invesco Ltd. now owns 1,969,326 shares of the company's stock worth $114,280,000 after purchasing an additional 696,923 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in Doximity by 8.5% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,579,708 shares of the company's stock valued at $84,341,000 after buying an additional 124,216 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Doximity by 4.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,576,455 shares of the company's stock valued at $84,167,000 after buying an additional 63,815 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Doximity by 9.4% in the 4th quarter. Northern Trust Corp now owns 1,459,185 shares of the company's stock valued at $77,906,000 after buying an additional 125,332 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on DOCS shares. Zacks Research downgraded shares of Doximity from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Needham & Company LLC boosted their price objective on shares of Doximity from $67.00 to $75.00 and gave the company a "buy" rating in a research report on Friday, August 8th. The Goldman Sachs Group set a $50.00 price target on shares of Doximity and gave the company a "neutral" rating in a research report on Wednesday, May 21st. Robert W. Baird reduced their price target on shares of Doximity from $87.00 to $65.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 20th. Finally, Bank of America boosted their price target on shares of Doximity from $55.00 to $62.00 and gave the company a "neutral" rating in a research report on Wednesday, June 25th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and eleven have given a Hold rating to the company's stock. According to MarketBeat, Doximity currently has an average rating of "Moderate Buy" and an average target price of $66.21.

Insider Buying and Selling

In related news, Director Kira Scherer Wampler sold 2,000 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $57.09, for a total transaction of $114,180.00. Following the sale, the director owned 16,618 shares of the company's stock, valued at $948,721.62. The trade was a 10.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Regina M. Benjamin sold 5,000 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $63.00, for a total transaction of $315,000.00. Following the completion of the transaction, the director owned 16,618 shares in the company, valued at approximately $1,046,934. This represents a 23.13% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,000 shares of company stock valued at $2,140,940 over the last quarter. Corporate insiders own 31.30% of the company's stock.

Doximity Price Performance

NASDAQ:DOCS traded up $0.95 during mid-day trading on Wednesday, hitting $68.03. 1,461,012 shares of the company's stock were exchanged, compared to its average volume of 2,301,628. Doximity, Inc. has a one year low of $35.32 and a one year high of $85.21. The business has a fifty day moving average price of $61.39 and a 200 day moving average price of $60.51. The company has a market cap of $12.74 billion, a PE ratio of 68.03, a P/E/G ratio of 4.10 and a beta of 1.36.

Doximity (NASDAQ:DOCS - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. During the same quarter last year, the company earned $0.28 EPS. Doximity's revenue was up 15.2% on a year-over-year basis. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. On average, equities analysts forecast that Doximity, Inc. will post 0.99 EPS for the current fiscal year.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.